ABSTRACT The present study reports the changes in configuration of maximal flow-volume curves after eight weeks' treatment with inhaled corticosteroids in 14 asthmatic patients. The configuration was compared with that seen after bronchodilatation following inhalation of a single dose of ipratropium bromide. After inhaled corticosteroids the shape of the flow-volume curves was less bowcd toward the volume axis, whereas the shape of the flow-volume curves after inhalation of ipratropium bromide showed no significant change. A significant correlation was observed between the decrease in blood eosinophil cell count and the straightening of the flow-volume curves, quantitatively expressed as shape factor and slope ratio. It is concluded that these changes in flowvolume curve configuration reflect a decrease in inhomogeneously distributed inflammatory airway narrowing.
Introduction
Bronchial obstruction in asthmatic patients is generally thought to be determined by bronchial smooth muscle contraction and by inflammatory processes in the bronchial wall.' Both factors can be treated separately. Inflammatory processes can be reduced by drugs such as corticosteroids, and smooth muscle contraction can be relieved by bronchodilating agents such as anticholinergic or sympathicomimetic drugs. Although corticosteroids and bronchodilators act in different ways, both drugs improve the forced expiratory volume in one second (FEV,) . Bronchodilatation is achieved in a short time after administration of the bronchodilator, but anti-inflammatory treatment takes several weeks to be effective, owing to the nature of inflammatory processes. In patients with mild asthma a rise in FEV, to their predicted values is often seen after administration of a bronchodilator, and such a change may occur after treatment with inhaled corticosteroids.2 Other measures of pulmonary function could, however, show differences between the rapid bronchodilatation seen with bronchodilator drugs and the bronchodilatation occurring over several weeks with anti-inflammatory treatment.
Maximal expiratory flow-volume (MEFV) curves are generally thought to give additional information about the severity of bronchial obstruction.34 The mechanical factors underlying airflow limitation during a forced expiration have received considerably more attention than the assessment of bronchial obstruction. On the basis of wave speed mechanics, Dawson and Elliott5 concluded that the flow limiting segment moves towards the peripheral airways with decreasing remaining lung volume. Measuring flows at different lung volumes may therefore give an approximate indication of the site of airway obstruction.
In clinical practice flow-volume curves are usually analysed in terms ofmaximum flows at a given volume and often interpreted qualitatively with regard to the shape of the curve. Even in patients with mild bronchial obstruction67 the flow-volume curves are more bowed towards the volume axis, and the question arises whether this increased convexity of the flow-volume curves reflects a specific pathological process that eventually may be influenced by treatment.
Several ways of quantifying the shape of an MEFV curve have been put forward. Mead' developed the slope ratio (SR), defined as tangent slope (dV/dV) divided by the chord V/(FVC-V), as an index of curvilinearity of the MEFV curve. He introduced also the ratio 1/2(VE max50/VE max25), here referred to as the shape factor at 50% remaining FVC (SF 50%) as 1016 an index of non-linearity of the MEFV curve.0 To extend the indices for curvilinearity of the MEFV curves over a larger lung volume, we calculated a similar index, making use of the flow at 75% remaining FVC: 1/3(VE max,5/VE max25), the shape factor at 75% (fig 1) .
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Results
Changes in lung function with budesonide and ipratropium are summarised in table 2. There were no significant differences between the baseline values before the two treatments, indicating that six weeks after cessation of budesonide the MEFV curve had Table 3 Measures (mean (SEM)) of the shape of the maximal expiratoryflow-volume curve In this study treatment with both budesonide for eight weeks and a single dose of ipratropium bromide increase FEV,. Budesonide had a larger effect, however, on end expiratory maximal flows than ipratropium bromide. This may partly be due to the fact that end expiratory maximal flow values are numerically smaller and show wide variability. As the variability for these flows appears to be of the same order of magnitude as that for other maximal expiratory flow values in our patients (table 2), the differences we report are likely to reflect differences in the action of budesonide and ipratropium bromide.
End expiratory flow rates are frequently used to assess bronchodilator responses.'3 The present study shows that possible changes in curvilinearity of the 
1020
MEFV curve also need to be taken into account. In this study we quantified the curvilinearity of the MEFV curves and showed that treatment with budesonide caused a decrease in curvilinearity, whereas treatment with ipratropium bromide had no such effect. The straightening effect of budesonide on the MEFV curve was seen with all three methods of quantifying the curvilinearity, though the methods that used VE max75 were more sensitive. The slope ratio at 50% FVC showed a non-significant difference whereas the change in slope ratio at 75% FVC was significant. Before treatment with budesonide there appears to be a decrease in slope ratio with decreasing lung volume. This confirms the findings of O'Donnell and coworkers,'5 who observed a similar decrease in subjects with mild asthma. They also found no such change in slope ratio in normal subjects. Kraan, van der Mark, Koeter shown on theoretical grounds that when such inhomogeneity occurs the flow-volume curve should be convex towards the volume axis. This has also been seen by O'Donnell'5 in asthmatic subjects, by Landau20 in patients with more advanced chronic obstructive lung disease, and recently by Kapp et al2' in an epidemiological study. The increased curvilinearity of the MEFV curve may therefore be caused by regional inhomogeneity of forced expiratory flow-that is, the existence of regions with a different time constant (flow divided by volume) in the lung.8 Our results might therefore suggest that inhaled corticosteroid drugs improve regional ventilatory inhomogeneity whereas rapid bronchodilatation with ipratropium does not exert such an effect, though the overall time constant was decreased.
Bronchial obstruction in asthma seems to be the consequence of smooth muscle contraction and increased thickness of the airway wall caused by inflammatory processes.' The inflammatory changes are seen in central and peripheral airways. Budesonide has a strong anti-inflammatory effect9 and this is thought to account for the fall in peripheral blood eosinophils during treatment with budesonide. As budesonide has low oral bioavailability when inhaled,9 we assume that the decrease in peripheral blood eosinophils is due to inhaled and not ingested drug. The fact that we found a correlation between change in peripheral blood eosinophils and change in curvilinearity of the MEFV curve suggests that inflammatory processes might be responsible for the abnormal shape of the MEFV curve in asthmatic patients. Limitation of expiratory flow is related not only to airway narrowing but also to the mechanical properties of the airway wall, in particular to airway compliance,5 and airway wall thickening due to inflammation may be an important cause of flow limitation. Such changes in the thickness of the airway wall are unlikely to be spread uniformly throughout the airways, and this may lead to inhomogeneous emptying during forced expiration.
Ipratropium bromide is a powerful bronchodilator. 
